A Phase 3 interventional study of Ixabepilone + Capecitabine and Capecitabine in Breast Cancer and Metastases, sponsored by R-Pharm. Completed at 127 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-02.
Sponsored by R-Pharm · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.
Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2003, is one of 5 in phase 3, and was the 7th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 29 · Phase 3 5
First in 2000; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 752 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 39 interventional studies. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 41 have an industry lead sponsor. The 10 most frequent:
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
15 studies in Breast Neoplasms by R-Pharm: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Breast Neoplasms by R-Pharm, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2003, is one of 3 in phase 3, and was the 3rd registered.
R-Pharm’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing ixabepilone in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00877500M.D. Anderson Cancer CenterIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing ixabepilone in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among R-Pharm’s 15 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ixabepilone + Capecitabine
Drug: Capecitabine
Drug pages: Ixabepilone · Capecitabine
Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Also known as: BMS-247550, IXEMPRA, Epothilone
Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)
PFS defined as the time in months from randomization to date of progression. Patients who died without a reported prior progression were considered to have progressed on date of death; those who didn't progress or die were censored on date of last tumor assessment. Median PFS time with 95% CI estimated using the Kaplan Meier product limit method.
Time frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
Overall Response Rate (ORR) Per IRRC
Participants with best response of "Complete" or "Partial" according to Response Evaluation Criteria in Solid Tumors (RECIST) a 4-item scale wherein complete response=disappearance of all target lesions and partial response=30% decrease in the sum of the longest diameter of target lesions
Time frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
Duration of Response Per IRRC
Computed for all patients with a best response of "Partial" or "Complete" per RECIST (a 4-item scale as described in previous outcome measure), calculated from the time when these criteria were first met until the first date of documented progression or death.
Time frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
Time to Response Per IRRC
Time to response was summarized using descriptive statistics and was defined as the time from first dose of study treatment until measurement criteria were first met for Partial Response or Complete Response.
Time frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
Overall Survival (OS)
OS was defined as the time from randomization to death. Participants who did not die at the time of the analysis were censored at the latest follow-up date. Median OS with 95% CI was estimated using the Kaplan Meier product limit method.
Time frame: from date of randomization until death
Treatment-related Safety Summary
Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0
Time frame: safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.
Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.
Time frame: Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment.
| Milestone | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Started | 375 | 377 |
| Never treated | 5 | 10 |
| Still on treatment | 0 | 1 |
| Completed | 370 | 366 |
| Not completed | 5 | 11 |
| Withdrew: Randomized but never treated | 5 | 10 |
| Withdrew: Still on treatment as of csr date | 0 | 1 |
PFS defined as the time in months from randomization to date of progression. Patients who died without a reported prior progression were considered to have progressed on date of death; those who didn't progress or die were censored on date of last tumor assessment. Median PFS time with 95% CI estimated using the Kaplan Meier product limit method.
| Months | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) | 5.85 (5.45 to 6.97) | 4.17 (3.81 to 4.50) |
Participants with best response of "Complete" or "Partial" according to Response Evaluation Criteria in Solid Tumors (RECIST) a 4-item scale wherein complete response=disappearance of all target lesions and partial response=30% decrease in the sum of the longest diameter of target lesions
| percent | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Overall Response Rate (ORR) Per IRRC | 34.7 (29.9 to 39.7) | 14.3 (10.9 to 18.3) |
Computed for all patients with a best response of "Partial" or "Complete" per RECIST (a 4-item scale as described in previous outcome measure), calculated from the time when these criteria were first met until the first date of documented progression or death.
| months | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Duration of Response Per IRRC | 6.4 (5.6 to 7.1) | 5.6 (4.2 to 7.5) |
Time to response was summarized using descriptive statistics and was defined as the time from first dose of study treatment until measurement criteria were first met for Partial Response or Complete Response.
| weeks | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Time to Response Per IRRC | 11.7 (4.4 to 61.4) | 12.0 (4.3 to 41.9) |
OS was defined as the time from randomization to death. Participants who did not die at the time of the analysis were censored at the latest follow-up date. Median OS with 95% CI was estimated using the Kaplan Meier product limit method.
| Months | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Overall Survival (OS) | 12.9 (11.5 to 14.2) | 11.1 (10.0 to 12.5) |
Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0
| Participants | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Deaths on-study or within 30 days of last dose | 33 | 40 |
| Treatment-related Serious Adverse Events (SAEs) | 91 | 31 |
| Treatment-related Adverse Events (AEs) | 357 | 330 |
| Treatment-related AEs leading to Discontinuation | 137 | 25 |
Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.
| units on a scale | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Week 3 (n=282; n=273) | -0.4 (-0.97 to 0.20) | 0.3 (-0.28 to 0.84) |
| Week 6 (n=227; n=214) | -0.2 (-0.90 to 0.48) | 1.1 (0.30 to 1.83) |
| Week 9 (n=194; n=184) | -0.6 (-1.31 to 0.19) | 1.8 (0.97 to 2.58) |
| Week 12 (n=173; n=158) | -1.3 (-2.19 to -0.42) | 1.4 (0.55 to 2.18) |
| Week 15 (n=148; n=145) | -0.7 (-1.65 to 0.27) | 1.7 (0.73 to 2.72) |
| Week 18 (n=122; n=121) | -1.0 (-2.18 to 0.13) | 1.7 (0.76 to 2.63) |
| Week 21 (n=116; n=101) | -0.7 (-1.63 to 0.28) | 1.1 (0.01 to 2.21) |
| Week 24 (n=95; n=82) | -0.8 (-1.89 to 0.38) | 2.3 (1.13 to 3.41) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine | — | 127/368 (34.5%) | 350/368 (95.1%) |
| Ixabepilone + Capecitabine | — | 151/369 (40.9%) | 360/369 (97.6%) |
| Event | Capecitabine | Ixabepilone + Capecitabine |
|---|---|---|
| MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 36/368 | 19/369 |
| NEUTROPENIABlood and lymphatic system disorders | 0/368 | 18/369 |
| PNEUMONIAInfections and infestations | 3/368 | 17/369 |
| DIARRHOEAGastrointestinal disorders | 15/368 | 14/369 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 4/368 | 15/369 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 7/368 | 14/369 |
| VOMITINGGastrointestinal disorders | 8/368 | 12/369 |
| ANAEMIABlood and lymphatic system disorders | 3/368 | 11/369 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 9/368 | 6/369 |
| PYREXIAGeneral disorders | 3/368 | 9/369 |
| Event | Capecitabine | Ixabepilone + Capecitabine |
|---|---|---|
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders | 228/368 | 235/369 |
| NAUSEAGastrointestinal disorders | 164/368 | 209/369 |
| DIARRHOEAGastrointestinal disorders | 147/368 | 179/369 |
| FATIGUEGeneral disorders | 97/368 | 160/369 |
| VOMITINGGastrointestinal disorders | 106/368 | 158/369 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 30/368 | 139/369 |
| MYALGIAMusculoskeletal and connective tissue disorders | 24/368 | 130/369 |
| ANOREXIAMetabolism and nutrition disorders | 69/368 | 127/369 |
| ALOPECIASkin and subcutaneous tissue disorders | 16/368 | 121/369 |
| CONSTIPATIONGastrointestinal disorders | 57/368 | 120/369 |
| Age, Customized(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| <65 years | 336 | 322 | 658 |
| >= 65 years | 39 | 54 | 93 |
| <50 years | 135 | 145 | 280 |
| >= 50 years | 240 | 231 | 471 |
| Unknown | 0 | 1 | 1 |
| Age, Continuous(years) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Median | 53.0 (25.0 to 76.0) | 52.0 (25.0 to 79.0) | 53.0 (25.0 to 79.0) |
| Sex: Female, Male(Participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Female | 375 | 376 | 751 |
| Male | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 83 | 87 | 170 |
| Black or African American | 11 | 11 | 22 |
| White | 257 | 247 | 504 |
| Other | 23 | 32 | 55 |
| Disease Sites(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Ascites | 14 | 14 | 28 |
| Bone | 168 | 162 | 330 |
| Breast | 61 | 63 | 124 |
| Chest Wall | 53 | 53 | 106 |
| Effusion | 57 | 55 | 112 |
| Lymph Node | 250 | 249 | 499 |
| Other | 20 | 18 | 38 |
| Peritoneum | 7 | 14 | 21 |
| Pleura | 29 | 35 | 64 |
| Skin/Soft Tissue | 60 | 62 | 122 |
| Visceral, Liver | 245 | 228 | 473 |
| Visceral, Lung | 180 | 174 | 354 |
| Visceral, Other | 34 | 28 | 62 |
| Disease Sites at Baseline(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Liver ± Lung ± Skin/Soft Tissue ± Bone | 245 | 228 | 473 |
| Lung ± Skin/Soft Tissue ± Bone | 71 | 87 | 158 |
| Skin/Soft Tissue ± Bone | 49 | 52 | 101 |
| Bone | 0 | 3 | 3 |
| Other | 6 | 5 | 11 |
| Karnofsky Performance Status(Units on a scale) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| 100 | 108 | 105 | 213 |
| 90 | 145 | 132 | 277 |
| 80 | 86 | 102 | 188 |
| 70 | 33 | 34 | 67 |
| <70 | 0 | 1 | 1 |
| Not reported | 3 | 3 | 6 |
| Menopausal Status(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Premenopausal | 54 | 51 | 105 |
| Perimenopausal | 19 | 23 | 42 |
| Postmenopausal | 288 | 289 | 577 |
| Not reported | 14 | 14 | 28 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 127 sites across 22 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2003, a primary completion of Nov 2006 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixabepilone · Capecitabine